Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 8 | 2023 | 81 | 3.770 |
Why?
|
| Ileostomy | 3 | 2025 | 31 | 2.030 |
Why?
|
| Patient Readmission | 4 | 2025 | 418 | 1.700 |
Why?
|
| Neoadjuvant Therapy | 4 | 2020 | 404 | 1.280 |
Why?
|
| Postoperative Complications | 6 | 2025 | 3167 | 1.240 |
Why?
|
| Crohn Disease | 4 | 2019 | 286 | 1.110 |
Why?
|
| Laparoscopy | 3 | 2023 | 513 | 0.970 |
Why?
|
| Robotic Surgical Procedures | 2 | 2021 | 226 | 0.960 |
Why?
|
| Fluid Therapy | 1 | 2025 | 149 | 0.870 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1213 | 0.860 |
Why?
|
| Length of Stay | 3 | 2025 | 1387 | 0.820 |
Why?
|
| Pelvis | 2 | 2023 | 74 | 0.770 |
Why?
|
| Narcotics | 1 | 2022 | 64 | 0.750 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2021 | 401 | 0.730 |
Why?
|
| Deoxycytidine | 1 | 2021 | 84 | 0.690 |
Why?
|
| Colectomy | 2 | 2022 | 84 | 0.680 |
Why?
|
| Ileum | 3 | 2019 | 136 | 0.660 |
Why?
|
| Robotics | 1 | 2021 | 109 | 0.660 |
Why?
|
| Simulation Training | 1 | 2021 | 146 | 0.620 |
Why?
|
| Quality Improvement | 1 | 2025 | 695 | 0.610 |
Why?
|
| General Surgery | 2 | 2019 | 218 | 0.600 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 282 | 0.600 |
Why?
|
| Biological Factors | 1 | 2018 | 27 | 0.590 |
Why?
|
| Colorectal Surgery | 1 | 2018 | 11 | 0.590 |
Why?
|
| Colonic Neoplasms | 2 | 2021 | 271 | 0.590 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 34 | 0.580 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 650 | 0.550 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 168 | 0.540 |
Why?
|
| Preoperative Care | 2 | 2018 | 375 | 0.530 |
Why?
|
| Peritoneal Diseases | 1 | 2016 | 8 | 0.530 |
Why?
|
| Students, Medical | 1 | 2021 | 367 | 0.520 |
Why?
|
| Hirschsprung Disease | 1 | 2016 | 37 | 0.520 |
Why?
|
| Medical Oncology | 1 | 2018 | 245 | 0.520 |
Why?
|
| Florida | 3 | 2025 | 79 | 0.510 |
Why?
|
| Abscess | 1 | 2016 | 140 | 0.470 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 153 | 0.470 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 320 | 0.460 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 562 | 0.430 |
Why?
|
| Pelvic Neoplasms | 1 | 2013 | 24 | 0.420 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 466 | 0.410 |
Why?
|
| Myxoma | 1 | 2013 | 30 | 0.410 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 1388 | 0.380 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 717 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1339 | 0.350 |
Why?
|
| Dissection | 2 | 2023 | 58 | 0.340 |
Why?
|
| Internship and Residency | 2 | 2019 | 1251 | 0.340 |
Why?
|
| Middle Aged | 11 | 2025 | 29296 | 0.340 |
Why?
|
| Humans | 29 | 2025 | 133717 | 0.340 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 39 | 0.340 |
Why?
|
| Telemedicine | 1 | 2017 | 500 | 0.330 |
Why?
|
| Retrospective Studies | 7 | 2024 | 17421 | 0.330 |
Why?
|
| Male | 16 | 2025 | 65858 | 0.320 |
Why?
|
| Aged | 9 | 2025 | 21679 | 0.310 |
Why?
|
| Postoperative Period | 2 | 2022 | 343 | 0.310 |
Why?
|
| Fluorouracil | 2 | 2021 | 141 | 0.310 |
Why?
|
| Female | 16 | 2025 | 71608 | 0.270 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 972 | 0.270 |
Why?
|
| Treatment Outcome | 6 | 2021 | 13003 | 0.260 |
Why?
|
| Lymphocytes | 2 | 2019 | 441 | 0.250 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1309 | 0.230 |
Why?
|
| Adult | 8 | 2024 | 31876 | 0.230 |
Why?
|
| Pakistan | 1 | 2024 | 94 | 0.220 |
Why?
|
| Infusions, Intravenous | 1 | 2025 | 571 | 0.210 |
Why?
|
| Clinical Protocols | 1 | 2024 | 245 | 0.200 |
Why?
|
| Cohort Studies | 2 | 2024 | 5194 | 0.190 |
Why?
|
| Morphine | 1 | 2022 | 86 | 0.190 |
Why?
|
| Perioperative Care | 1 | 2024 | 219 | 0.180 |
Why?
|
| Prognosis | 3 | 2021 | 5073 | 0.180 |
Why?
|
| Capecitabine | 1 | 2021 | 18 | 0.180 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2018 | 89 | 0.170 |
Why?
|
| Career Choice | 1 | 2021 | 162 | 0.160 |
Why?
|
| Rectum | 1 | 2020 | 113 | 0.160 |
Why?
|
| Standard of Care | 1 | 2020 | 135 | 0.160 |
Why?
|
| Pain | 1 | 2022 | 482 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2018 | 3711 | 0.150 |
Why?
|
| Pain, Postoperative | 1 | 2021 | 278 | 0.150 |
Why?
|
| Community Networks | 1 | 2018 | 33 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2021 | 701 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2018 | 93 | 0.140 |
Why?
|
| United States | 4 | 2022 | 11709 | 0.140 |
Why?
|
| Operative Time | 1 | 2018 | 184 | 0.140 |
Why?
|
| Hernia | 1 | 2017 | 18 | 0.140 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 158 | 0.140 |
Why?
|
| Cadaver | 1 | 2017 | 138 | 0.140 |
Why?
|
| Perineum | 1 | 2017 | 48 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 230 | 0.140 |
Why?
|
| Immunity, Innate | 2 | 2019 | 416 | 0.130 |
Why?
|
| Surgical Mesh | 1 | 2017 | 70 | 0.130 |
Why?
|
| Dehydration | 1 | 2017 | 42 | 0.130 |
Why?
|
| Leadership | 1 | 2019 | 246 | 0.130 |
Why?
|
| Herniorrhaphy | 1 | 2017 | 83 | 0.130 |
Why?
|
| Mesentery | 1 | 2016 | 27 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 1352 | 0.130 |
Why?
|
| Age of Onset | 1 | 2018 | 636 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2025 | 6589 | 0.130 |
Why?
|
| Schools, Medical | 1 | 2017 | 125 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 87 | 0.130 |
Why?
|
| Fibrosis | 1 | 2018 | 462 | 0.130 |
Why?
|
| Lymphocyte Subsets | 1 | 2016 | 41 | 0.130 |
Why?
|
| Telephone | 1 | 2017 | 127 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2019 | 282 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 97 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 315 | 0.120 |
Why?
|
| Young Adult | 3 | 2018 | 9873 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2017 | 187 | 0.120 |
Why?
|
| Surgical Flaps | 1 | 2017 | 196 | 0.120 |
Why?
|
| Counseling | 1 | 2017 | 239 | 0.120 |
Why?
|
| Inflammation | 3 | 2019 | 1591 | 0.120 |
Why?
|
| Carcinoma | 1 | 2017 | 322 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2018 | 1596 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2021 | 1068 | 0.110 |
Why?
|
| Colonic Diseases | 1 | 2014 | 38 | 0.110 |
Why?
|
| Intestines | 1 | 2018 | 615 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 326 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2018 | 776 | 0.110 |
Why?
|
| Intussusception | 1 | 2014 | 55 | 0.110 |
Why?
|
| Sacrococcygeal Region | 1 | 2013 | 34 | 0.100 |
Why?
|
| Logistic Models | 1 | 2018 | 1908 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 484 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2017 | 1487 | 0.100 |
Why?
|
| Survival Rate | 1 | 2018 | 2217 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 2297 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2018 | 1713 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1717 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2989 | 0.090 |
Why?
|
| Coercion | 1 | 2011 | 26 | 0.090 |
Why?
|
| Culture | 1 | 2011 | 73 | 0.090 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 815 | 0.090 |
Why?
|
| Adolescent | 2 | 2018 | 20522 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 2011 | 402 | 0.070 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 2 | 2 | 2019 | 4 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2019 | 65 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 3991 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 7196 | 0.060 |
Why?
|
| Physicians | 1 | 2011 | 638 | 0.060 |
Why?
|
| Risk Factors | 1 | 2018 | 11112 | 0.050 |
Why?
|
| Catastrophization | 1 | 2021 | 18 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 16 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2020 | 34 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2021 | 368 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 134 | 0.040 |
Why?
|
| Interleukin-23 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Sexism | 1 | 2019 | 42 | 0.040 |
Why?
|
| Tyrosine | 1 | 2019 | 159 | 0.040 |
Why?
|
| Gender Identity | 1 | 2019 | 72 | 0.040 |
Why?
|
| Elasticity | 1 | 2018 | 93 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2018 | 130 | 0.040 |
Why?
|
| Autografts | 1 | 2017 | 29 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 379 | 0.030 |
Why?
|
| Species Specificity | 1 | 2018 | 570 | 0.030 |
Why?
|
| Cattle | 1 | 2018 | 587 | 0.030 |
Why?
|
| Ascites | 1 | 2017 | 99 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2016 | 21 | 0.030 |
Why?
|
| Receptors, Prostaglandin | 1 | 2016 | 22 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2016 | 93 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2016 | 126 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 342 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1385 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 312 | 0.030 |
Why?
|
| Pain Management | 1 | 2017 | 202 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1707 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 1215 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 369 | 0.030 |
Why?
|
| Malnutrition | 1 | 2017 | 218 | 0.030 |
Why?
|
| Gene Expression | 1 | 2018 | 1616 | 0.030 |
Why?
|
| Uterus | 1 | 2017 | 585 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 461 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 2239 | 0.020 |
Why?
|
| Afghanistan | 1 | 2011 | 17 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 3430 | 0.020 |
Why?
|
| Religion | 1 | 2011 | 51 | 0.020 |
Why?
|
| Leg | 1 | 2011 | 157 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 4841 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 5468 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4793 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2173 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3843 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 36424 | 0.010 |
Why?
|